It's more than a result.
It's a person.

We're Driven To Know.
genetics-icon
Genetics

Innovative solutions that empower researchers, from ALS to fragile X syndrome.

Learn more about our Genetics portfolio
oncology-icon
Oncology

Solving complex molecular challenges, from leukemia to solid tumors.

Learn more about our Oncology portfolio
cdx-icon
Custom & Companion Diagnostics

One partner from clinical concept to product commercialization.

Learn more about partnering with us.
Spotlight

Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer

Asuragen expands CE mark of the QuantideX® qPCR BCR-ABL IS Kit and QuantideX® qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer.

Read More
Spotlight

Asuragen Expands Portfolio into Alzheimer’s & Cognitive Impairment Space

Asuragen launches AmplideX® PCR/CE TOMM40 RUO Kit to advance studies of neurodegeneration, dementia progression and Alzheimer’s disease.

Read more
Spotlight

Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio

Expansion of the CE-marked BCR-ABL Portfolio offers high quality, ultra-sensitive Major & minor fusion detection for monitoring CML patients.

Learn more

The Latest from Asuragen

AMP 2017 Workshop: Next-Generation Genotyping of Unstable DNA: Expanding AmplideX® PCR Technology Across Neurodegenerative and Neurodevelopmental Disorders
Press Release
Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference
Event
ESHG 2018: European Human Genetics Conference

Milan, Italy

Press Release
Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio for Monitoring Molecular Response in Chronic Myeloid Leukemia
Back To
Top